Having already hit the primary endpoint of overall response rate in the phase II/III Companion-002 study testing the bispecific antibody tovecimig in biliary tract cancer, Compass Therapeutics Inc. rolled out new data from the same experiment and plans to meet with the U.S. FDA to discuss a BLA. Shares of the Boston-based firm (NASDAQ:CMPX) closed April 27 at $1.79, down about 64%, or $3.23, as Wall Street sifted the results.